CTAD 2022 and Treatment View overview page

Lecanemab: a review

Lecanemab: drawbacks to consider

Lecanemab vs aducanumab

FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?

Targeting the pancreas to treat Alzheimer’s disease

Diabetes-associated cognitive dysfunction

The regulatory role of nicotinic receptors in cognitive functioning

New pivotal study using photobiomodulation in Alzheimer’s treatment

The importance of using systems biology based approaches in AD research

Highlights from CTAD 2022

How effective are cholinergic agents beyond MCI?

Prioritizing the mechanistic understanding of AD to improve treatments

Photobiomodulation: why target the brain and the gut?

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk

APOE-targeted epigenome therapy for Alzheimer’s disease

First-in-human clinical trial of the anti-PD-L1 antibody, IBC-Ab002, in early AD